









Markets
/
Stocks
/
nasdaq-inmb
/

INmune Bio Inc

INMB

1.510USD

+0.090+6.34%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

40.14MMarket Cap

LossP/E TTM



INmune Bio Inc

1.510

+0.090+6.34%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of INmune Bio Inc

Currency: USD Updated: 2026-02-06

Key Insights

INmune Bio Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 126 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.25.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

INmune Bio Inc's Score

Industry at a Glance

Industry Ranking

126 / 392

Overall Ranking

264 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

INmune Bio Inc Highlights

StrengthsRisks

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.

Growing

The company is in a growing phase, with the latest annual income totaling USD 14.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 14.00K.

Overvalued

The company’s latest PE is -0.73, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 4.63M shares, decreasing 40.75% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 957.85K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 1.74.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

5.250

Target Price

+269.72%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of INmune Bio Inc is 7.58, ranking 97 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.60

Change

-0.02



Financials

9.84

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.59

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.85

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.60

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

INmune Bio Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of INmune Bio Inc is 8.16, ranking 58 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.73, which is -5.97% below the recent high of -0.68 and -1056.79% above the recent low of -8.39.

Score

Industry at a Glance

Previous score

8.16

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 126/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of INmune Bio Inc is 7.50, ranking 284 out of 392 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 21.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

7.50

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

5.250

Target Price

+269.72%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

INmune Bio Inc

INMB

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of INmune Bio Inc is 5.30, ranking 322 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.74 and the support level at 1.35, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.99

Change

0.31

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.026

Sell

RSI(14)

44.001

Neutral

STOCH(KDJ)(9,3,3)

18.855

Oversold

ATR(14)

0.117

Low Volatility

CCI(14)

-92.310

Neutral

Williams %R

74.359

Sell

TRIX(12,20)

-0.266

Sell

StochRSI(14)

76.883

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.516

Sell

MA10

1.581

Sell

MA20

1.591

Sell

MA50

1.697

Sell

MA100

1.756

Sell

MA200

3.219

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of INmune Bio Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 17.40%, representing a quarter-over-quarter decrease of 19.71%. The largest institutional shareholder is The Vanguard, holding a total of 957.85K shares, representing 3.60% of shares outstanding, with 1.17% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Tesi (Raymond Joseph)

1.55M

Lowdell (Mark William)

1.51M

Moss (David J.)

1.29M

BlackRock Institutional Trust Company, N.A.

1.10M

+5.29%

The Vanguard Group, Inc.

Star Investors

876.29K

+3.37%

Geode Capital Management, L.L.C.

469.44K

+20.39%

State Street Investment Management (US)

283.83K

+3.07%

Raymond James Financial Services Advisors, Inc.

253.50K

-20.02%

Northern Trust Investments, Inc.

182.38K

+12.26%

Susquehanna International Group, LLP

156.95K

+686.93%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of INmune Bio Inc is 2.99, ranking 179 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.76. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.